Managing uncomplicated typhoid fever remains a major public health priority across South Asia. Enteric fever continues to impose a substantial burden on healthcare systems, particularly because antimicrobial resistance limits reliable empirical oral therapies. Historically, clinicians relied heavily on fluoroquinolones, but widespread bacterial resistance forced international guidelines to endorse macrolides. The World Health Organization currently recommends oral azithromycin monotherapy as a first-line treatment for uncomplicated enteric disease. However, physicians frequently prescribe combination therapy with cefixime in outpatient settings to achieve both intracellular and extracellular pathogen clearance. The landmark ACT-South Asia randomized clinical trial evaluated whether adding oral cefixime to azithromycin improves clinical cure or reduces treatment failures.

ACT-South Asia Trial Design and Methodology

The ACT-South Asia study was a rigorous, phase 4, double-blind, parallel-group, placebo-controlled trial conducted across Nepal, Bangladesh, and Pakistan. Researchers recruited both pediatric and adult outpatients aged 2 to 65 years presenting with acute undifferentiated febrile illness lasting 3 to 14 days. To ensure accurate patient selection, investigators required a serum C-reactive protein level of at least 10 mg/L alongside negative diagnostic tests for malaria, dengue, scrub typhus, and COVID-19. Participants were randomly assigned in a 1:1 ratio to receive either oral azithromycin with oral cefixime or oral azithromycin with a matching placebo for 7 consecutive days.

Specifically, patients received weight-based dosing consisting of azithromycin at 20 mg/kg once daily up to a maximum dose of 1 g daily, paired with cefixime at 10 mg/kg twice daily up to a maximum dose of 400 mg twice daily. The primary outcome was a composite endpoint of treatment failure within 28 days of follow-up. This composite measure captured fever clearance exceeding 7 days, microbiological failure by day 7, necessity for rescue antimicrobial therapy, typhoid complications, or disease relapse. Allocation concealment and strict blinding ensured robust data integrity across all international study sites.

Key Findings in Uncomplicated Typhoid Fever Management

Between May 2021 and September 2025, investigators screened 46,947 febrile individuals and randomized 1,847 eligible participants. The primary modified intention-to-treat analysis evaluated 1,831 patients, including 350 individuals with blood culture-confirmed Salmonella enterica serovars Typhi or Paratyphi. Notably, the trial demonstrated that the combination of azithromycin and cefixime provided no additional clinical benefit over azithromycin monotherapy.

In the overall modified intention-to-treat cohort, treatment failure occurred in 44 of 915 patients (5.1%) in the azithromycin-cefixime arm and exactly 44 of 916 patients (5.1%) in the azithromycin-placebo arm. This yielded an absolute risk difference of -0.00 percentage points with a 95% confidence interval ranging from -2.08 to 2.08 (p=1.00). Furthermore, among the subgroup of 350 patients with culture-confirmed disease, treatment failure occurred in 19 of 179 participants (10.6%) receiving dual therapy compared to 26 of 171 participants (15.2%) receiving monotherapy. This difference did not reach statistical significance, showing an absolute risk difference of 4.48 percentage points (95% CI -2.52 to 12.21; p=0.20). Consequently, these robust findings confirm that oral azithromycin monotherapy achieves high clinical cure rates without requiring additional cephalosporin coverage.

Safety Profiles and Clinical Outcomes

In addition to therapeutic efficacy, the ACT-South Asia trial meticulously assessed patient safety and tolerability across both treatment groups. Adverse events occurred with comparable frequency in both cohorts. Specifically, 142 of 918 participants (16%) in the azithromycin-cefixime group reported adverse events compared to 144 of 917 participants (16%) in the monotherapy group. Most reported events were mild and gastrointestinal in nature, including nausea, transient abdominal discomfort, and loose stools.

Serious adverse events requiring hospital admission were also infrequent and balanced between the arms. In total, 21 patients (2%) in the combination group and 17 patients (2%) in the monotherapy group experienced serious adverse events. Importantly, neither group demonstrated drug-related mortality or unexpected toxicities during the 28-day surveillance window. These safety data demonstrate that a standard 7-day course of high-dose azithromycin is safe and well tolerated across diverse age groups in endemic regions. Moreover, adding cefixime did not increase the rate of severe adverse reactions, but it did not provide any clinical advantage to justify its routine co-prescription.

Implications for Antimicrobial Stewardship in South Asia

These definitive findings carry vital implications for antimicrobial stewardship across South Asia and other resource-limited endemic settings. Clinicians often adopt empirical dual-antibiotic regimens because they fear monotherapy failure in regions with multidrug-resistant and extensively drug-resistant Salmonella strains. However, this study provides high-quality evidence demonstrating that dual therapy does not decrease treatment failure rates.

Routine addition of oral cephalosporins to macrolide therapy increases healthcare expenditures for vulnerable families and exposes patients to unnecessary medication without clinical gain. Furthermore, widespread overprescription of third-generation cephalosporins accelerates selective pressure for cephalosporin resistance among enteric pathogens and normal gut flora. Preserving cephalosporins is essential because parenteral ceftriaxone remains a crucial therapy for complicated and severe systemic typhoid infections. Therefore, practicing clinicians should adhere strictly to monotherapy regimens, reserving cephalosporins for situations where microbiological susceptibilities or specific clinical indications demand their use. This approach supports global stewardship goals while maintaining high standard-of-care cure rates.

Integrating Evidence into Clinical Decision-Making

Primary care physicians and pediatricians routinely encounter acute febrile illnesses in endemic settings and must make prompt therapeutic decisions. When treating uncomplicated enteric fever, clinicians should utilize validated risk stratification, objective inflammatory markers such as C-reactive protein, and rapid exclusion of other tropical fevers. Once clinicians suspect or confirm uncomplicated typhoid fever, they should initiate oral azithromycin monotherapy at 20 mg/kg once daily for 7 days.

Additionally, healthcare providers should counsel patients and caregivers regarding expected fever defervescence timelines. Because enteric fever resolves gradually, fever clearance often requires 4 to 6 days of compliant oral therapy. Premature switching of antibiotics or unnecessary escalation to combination therapy before adequate time has elapsed contributes directly to drug resistance. Clinicians should only consider rescue therapy or escalation if patients exhibit clinical deterioration, persistent high-grade fever past 7 days, or emergence of peritoneal signs. By following evidence-based monotherapy protocols, practitioners optimize clinical outcomes, minimize unnecessary drug costs, and safeguard valuable antimicrobial agents for future generations.

Frequently Asked Questions

Why is azithromycin monotherapy preferred over combination therapy with cefixime?

Azithromycin monotherapy achieves clinical cure rates identical to combination therapy with cefixime in uncomplicated enteric fever. The ACT-South Asia trial demonstrated an identical 5.1% treatment failure rate in both treatment arms. Therefore, adding cefixime exposes patients to additional medication costs and potential side effects without providing any measurable therapeutic advantage or faster fever resolution.

How long does fever typically take to resolve during azithromycin treatment for typhoid?

Fever clearance in uncomplicated enteric fever treated with oral azithromycin typically takes between 4 and 6 days. Clinicians should carefully avoid prematurely declaring treatment failure or switching antibiotics during the first few days of therapy. If systemic symptoms improve and serious danger signs are absent, patients should complete the full 7-day course of once-daily azithromycin to ensure complete microbiological eradication and prevent disease relapse.

Does cefixime provide any benefit for culture-confirmed multidrug-resistant typhoid cases?

Current clinical trial evidence demonstrates that adding cefixime to azithromycin does not significantly reduce treatment failures, even in culture-confirmed cases. In the ACT-South Asia trial, the failure rate between monotherapy and combination therapy in culture-positive participants showed no statistically significant difference. Thus, expert guidelines recommend oral azithromycin monotherapy as standard care for uncomplicated outpatient cases rather than empirical dual-agent cephalosporin addition.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. While we strive to present accurate, up-to-date evidence-based information, healthcare decisions should always be made in consultation with qualified healthcare professionals and in accordance with individual patient needs. Refer to the latest local and national guidelines for clinical practice.

References

1. Basnyat B et al. Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial. Lancet Infect Dis. 2026 Aug 20. doi: undefined. PMID: 42624818.


2. World Health Organization. Typhoid and other invasive salmonellosis: WHO guidelines on diagnosis, treatment and management. Geneva: World Health Organization; 2024.


3. Darton TC, et al. Azithromycin and cefixime combination versus azithromycin alone for the out-patient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomised controlled trial protocol. Wellcome Open Res. 2021;6:305.